This article is more than 5 years old. Information may no longer be current.

Rheo clinical trial for dry AMD completes enrollment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TORONTO – Patient enrollment in a pivotal phase 3 clinical trial of the Rheo System for the treatment of dry age-related macular degeneration has been completed, exceeding its goal of 180 patients, according to OccuLogix, the company running the trial.

A total of 185 patients have been enrolled in the Rheo System clinical trial, the company noted in a press release. The Multicenter Investigation of Rheopheresis for AMD is a randomized, placebo-controlled trial designed to evaluate the safety and effectiveness of the therapy in patients with intermediate to late-stage dry AMD, according to a company press release.

Enrolled patients will receive either eight Rheo procedures or placebo procedures over a 10-week period. The primary end point will be the measured change in best corrected visual acuity, with secondary endpoints including legal driving vision, vision loss, drusen reduction and progression to legal blindness.